HighLight Capital
Deal focus: Topolefin finds favour as import substitution play
China-based Topolefin has gained traction thanks to breakthroughs in polymer science and the willingness of local medical equipment makers to use its components in foreign-dominated supply chains
HighLight updates final close timeline for China healthcare fund
HighLight Capital, a Chinese life sciences investor, has pushed out the final close on its fourth US dollar-denominated fund to the third quarter amid challenging fundraising conditions for the industry.
South by Southeast: Asia’s next growth engine?
Grouping together markets based on growth and scale is a problematic with South Asia and Southeast Asia as it was with the BRIC economies. But to some extent, investors are buying into the story
VCs positive on SE Asia's fundamentals, strategic positioning - AVCJ Forum
Venture capital investors remain bullish about Southeast Asia's prospects despite a sharp decline in activity this year, noting that the region is strategically well placed amid the US-China tensions.
DEG leads round for Indonesian mRNA vaccine developer
German development finance organisation DEG has contributed USD 8m as the lead investor in a new funding round for Etana Biotechnologies Indonesia, supported by Yunfeng Capital, HighLight Capital, and East Ventures.
China's HighLight hits first close on life sciences fund, targets $650m
HighLight Capital, a China-based life sciences investor, has completed a first close of USD 540m on its fourth US dollar-denominated fund. The overall target is USD 650m.
Deal focus: Medilink chases global ADC opportunity
The Medilink Therapeutics team spun out from Kelun-Biotech to develop antibody drug conjugates capable of competing with the world’s best. Its USD 70m Series B will support the pursuit of this goal
Lyfe, Qiming lead Series B for China ADC player Medilink
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised a USD 70m Series B led by Lyfe Capital and Qiming Venture Partners.
China petcare brand raises $31m
Chongxing, a Chinese petcare brand, has raised RMB200 million ($31 million) in a third tranche of Series B funding from Tencent Holdings, Hony Capital, HighLight Capital, Vertex Ventures China, and Meridian Capital.
China’s Hope Medicine raises $56m Series B
Chinese innovative drug company Hope Medicine has raised a $56 million Series B round jointly led by Qiming Venture Partners and Grand Flight Investment.
China e-commerce enabler Xingyun raises $600m - update
China’s Xingyun Group, a digital supply chain provider for cross-border e-commerce, has raised $600 million in the second tranche of Series C round led by Yunfeng Capital, HI Transformational Fund, and Crescent Point.
China mRNA vaccine provider Abogen raises $92m
Suzhou Abogen Biosciences, a Chinese mRNA vaccine provider, has raised RMB600 million ($92 million) led by PICC Capital - an investment unit under People’s Insurance Company of China - and state-backed SDIC Venture Capital.
GL joins $61m Series C for China’s Thousand Oaks
GL Ventures - a VC unit of Hillhouse Capital - and China State-Owned Capital Venture Investment Fund have led a RMB400 million ($61 million) Series C round for Thousand Oaks Biopharmaceuticals, a China-based contract development and manufacturing organization...
The big C: China biotech start-ups get cutting edge on cancer
The evolution of cancer treatments in China is a bellwether for biotech development in the country and its capacity for genuine innovation. Most PE and VC investors aren’t shying away
Xiaomi-backed Soocas raises $25m pre-IPO round
Soocas, a Shenzhen-based electric toothbrush maker backed by smart phone maker Xiaomi has raised a RMB175 million ($25 million) pre-IPO round led by Grand Flight Investment Management.
China medical device player Hanyu Medical secures $72m
China-based medical devices manufacturer Hanyu Medical has raised a RMB500 million ($72 million) Series D co-led by HighLight Capital, CPE (formerly known as CITIC Private Equity), and Yingke Private Equity.
PE-backed Kintor Pharma raises $240m in Hong Kong IPO
Kintor Pharmaceutical, a Chinese drug developer backed by the likes of HighLight Capital and Shenzhen Green Pine Capital Partners, posted a 7% gain on debut following a HK$1.86 billion ($240 million) Hong Kong IPO.
China cancer diagnosis player ChosenMed gets Series B
ChosenMed, a Beijing-based tumor detection company has raised a Series B round of more than RMB100 million ($14 million) led by state-owned Shanghai Lianhe Investment.
HighLight-backed Zentalis raises $165m in US IPO
Zentalis Pharmaceuticals, a US-based cancer drug developer, raised $165.2 million in its NASDAQ IPO, facilitating a liquidity event for Chinese healthcare investment specialist HighLight Capital.
China’s GenFleet Therapeutics raises $50m Series B
CDH Investments and Shenzhen Capital Group have co-led a $50 million Series B round for GenFleet Therapeutics, a Chinese drug developer.
First responders: China VCs on a healthcare crisis
The coronavirus outbreak has thrust Chinese healthcare services into the spotlight, prompting investors to identify to sub-segments with potential for significant growth
HighLight hits $300m first close on China healthcare fund
Chinese healthcare-focused GP HighLight Capital has reached the first close of $300 million on its third US dollar-denominated fund, but further progress is likely to be delayed by the coronavirus outbreak.
Emerging Asia healthcare: Pilot programs
Buy-and-build strategies, a mainstay of the PE toolkit in developed markets, are gaining exposure in emerging Asia’s healthcare sector. Proving a viable exit path will be the key to widespread adoption
Sequoia China, HighLight back biotech player Cullgen
Sequoia Capital China and HighLight Capital have led a $16 million Series A round for Cullgen, a biotech company that develops treatments for cancer by targeting previously “undruggable” cellular proteins.